Hänel, Gerulf http://orcid.org/0000-0003-4685-6499
Schönle, Anne
Neumann, Anne-Sophie
Nixdorf, Daniel http://orcid.org/0000-0003-1612-9952
Philipp, Nora http://orcid.org/0000-0002-3918-7795
Sponheimer, Monika
Leutbecher, Alexandra
Emhardt, Alica-Joana
Magno, Giulia
Bücklein, Veit http://orcid.org/0000-0001-7391-7280
Eckmann, Jan
Dunshee, Diana
Kramar, Vesna
Korfi, Koorosh
Colombetti, Sara
Umaña, Pablo http://orcid.org/0000-0001-8206-2771
Klein, Christian http://orcid.org/0000-0001-7594-7280
Subklewe, Marion http://orcid.org/0000-0001-9154-9469
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (451580403, 452881907)
Wilhelm Sander-Stiftung (2018.087.1)
Else Kröner-Fresenius-Stiftung
Roche
Bavarian Elite Graduate Training Network Bavarian Center for Cancer Research
Article History
Received: 21 October 2023
Revised: 12 December 2023
Accepted: 14 December 2023
First Online: 11 January 2024
Competing interests
: AS, VK, KK, SC, PU and CK are employed at the Roche Innovation Center Zurich, Schlieren, Switzerland and JE is employed at the Roche Innovation Center Munich, Penzberg, Germany. These authors also declare patents and ownership of Roche stock. DD is employed at Genentech Inc., South San Francisco, CA. MSu has received industry research support from Amgen, Gilead, Miltenyi Biotec, Morphosys, Roche, and Seattle Genetics, and has served as a consultant/advisor to Amgen, BMS, Celgene, Gilead, Pfizer, Novartis, and Roche. She sits on the advisory boards of Amgen, Celgene, Gilead, Janssen, Novartis, Pfizer, and Seattle Genetics, and serves on the speakers’ bureau at Amgen, Celgene, Gilead, Janssen, and Pfizer. GH, ASN and MSu declare patents together with Roche. DN, NP, MSp, AL and VB declare no relevant competing interests.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was obtained by the Institutional Review Board of the LMU Munich.
: Informed consent was obtained from all individual participants included in the study.